Amelia S Wallace1,2, Alex R Chang3,4,5, Jung-Im Shin1,2, Jodie Reider6, Justin B Echouffo-Tcheugui7, Morgan E Grams1,2,8, Elizabeth Selvin1,2. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. 3. Department of Population and Health Sciences, Geisinger, Danville, PA, USA. 4. Kidney Health Research Institute, Geisinger, Danville, PA, USA. 5. Department of Nephrology, Geisinger, Danville, PA, USA. 6. Endocrinology, Diabetes & Metabolism, Internal Medicine, Geisinger, Danville, PA, USA. 7. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 8. Department of Internal Medicine, Division of Nephrology, Johns Hopkins University, Baltimore, MD, USA.
Abstract
OBJECTIVE: Obesity is a global public health challenge and strongly associated with type 2 diabetes (T2D), but its burden and effects are not well understood in people with type 1 diabetes (T1D). Particularly, the link between obesity and chronic kidney disease (CKD) in T1D is poorly characterized. RESEARCH DESIGN AND METHODS: We included all T1D and, for comparison, T2D in the Geisinger Health System from 2004 to 2018. We evaluated trends in obesity (body mass index ≥ 30 kg/m2), low estimated glomerular filtration rate (eGFR) (≤60 mL/min/1.73m2), and albuminuria (urine albumin-to-creatinine ratio ≥ 30 mg/g). We used multivariable logistic regression to evaluate the independent association of obesity with CKD in 2018. RESULTS: People with T1D were younger than T2D (median age 39 vs 62 years). Obesity increased in T1D over time (32.6% in 2004 to 36.8% in 2018), while obesity in T2D was stable at ~60%. The crude prevalence of low eGFR was higher in T2D than in T1D in all years (eg, 30.6% vs 16.1% in 2018), but after adjusting for age differences, prevalence was higher in T1D than T2D in all years (eg, 16.2% vs 9.3% in 2018). Obesity was associated with increased odds of low eGFR in T1D [adjusted odds ratio (AOR) = 1.52, 95% CI 1.12-2.08] and T2D (AOR = 1.29, 95% CI 1.23-1.35). CONCLUSIONS: Obesity is increasing in people with T1D and is associated with increased risk of CKD. After accounting for age, the burden of CKD in T1D exceeded the burden in T2D, suggesting the need for increased vigilance and assessment of kidney-protective medications in T1D.
OBJECTIVE: Obesity is a global public health challenge and strongly associated with type 2 diabetes (T2D), but its burden and effects are not well understood in people with type 1 diabetes (T1D). Particularly, the link between obesity and chronic kidney disease (CKD) in T1D is poorly characterized. RESEARCH DESIGN AND METHODS: We included all T1D and, for comparison, T2D in the Geisinger Health System from 2004 to 2018. We evaluated trends in obesity (body mass index ≥ 30 kg/m2), low estimated glomerular filtration rate (eGFR) (≤60 mL/min/1.73m2), and albuminuria (urine albumin-to-creatinine ratio ≥ 30 mg/g). We used multivariable logistic regression to evaluate the independent association of obesity with CKD in 2018. RESULTS: People with T1D were younger than T2D (median age 39 vs 62 years). Obesity increased in T1D over time (32.6% in 2004 to 36.8% in 2018), while obesity in T2D was stable at ~60%. The crude prevalence of low eGFR was higher in T2D than in T1D in all years (eg, 30.6% vs 16.1% in 2018), but after adjusting for age differences, prevalence was higher in T1D than T2D in all years (eg, 16.2% vs 9.3% in 2018). Obesity was associated with increased odds of low eGFR in T1D [adjusted odds ratio (AOR) = 1.52, 95% CI 1.12-2.08] and T2D (AOR = 1.29, 95% CI 1.23-1.35). CONCLUSIONS: Obesity is increasing in people with T1D and is associated with increased risk of CKD. After accounting for age, the burden of CKD in T1D exceeded the burden in T2D, suggesting the need for increased vigilance and assessment of kidney-protective medications in T1D.
Authors: Jon Edqvist; Araz Rawshani; Martin Adiels; Lena Björck; Marcus Lind; Ann-Marie Svensson; Sofia Gudbjörnsdottir; Naveed Sattar; Annika Rosengren Journal: Diabetes Care Date: 2019-05-02 Impact factor: 19.112
Authors: Elizabeth Selvin; Jane Manzi; Lesley A Stevens; Frederick Van Lente; David A Lacher; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2007-12 Impact factor: 8.860
Authors: Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler Journal: N Engl J Med Date: 2020-09-24 Impact factor: 91.245
Authors: Jung-Im Shin; Alex Secora; G Caleb Alexander; Lesley A Inker; Josef Coresh; Alex R Chang; Morgan E Grams Journal: Clin J Am Soc Nephrol Date: 2018-07-12 Impact factor: 8.237
Authors: Jennifer N Todd; Emma H Dahlström; Rany M Salem; Niina Sandholm; Carol Forsblom; Amy J McKnight; Alexander P Maxwell; Eoin Brennan; Denise Sadlier; Catherine Godson; Per-Henrik Groop; Joel N Hirschhorn; Jose C Florez Journal: Diabetes Date: 2015-08-25 Impact factor: 9.461
Authors: An Tran-Duy; Josh Knight; Andrew J Palmer; Dennis Petrie; Tom W C Lung; William H Herman; Björn Eliasson; Ann-Marie Svensson; Philip M Clarke Journal: Diabetes Care Date: 2020-06-12 Impact factor: 19.112